Facebook Twitter Linkedin

Harnessing the Immune System

Harnessing the Immune System

See Pipeline
See Pipeline
Inimmune to present an update on clinical stage vaccine adjuvant and immunotherapy programs at the World Vaccine Congress in Washington DC on April 1st

Inimmune to present an update on clinical stage vaccine adjuvant and immunotherapy programs at the...

Read More
Inimmune Corporation and Intrommune therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy

Inimmune Corporation and Intrommune therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral...

Read More
Inimmune to present on their novel cancer immunotherapy INI-4001 at the Medinvest Oncology Conference on December 6th, 2023

Inimmune to present on their novel cancer immunotherapy INI-4001 at the Medinvest Oncology Conference on...

Read More
Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on our innovative vaccine and adjuvant programs on Wednesday, December 29, 2023 at the World Vaccine Congress (West Coast) in Santa Clara, CA.

Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on our...

Read More
Inimmune Collaborates with Boston Children's Hospital to Develop Novel Adjuvants

Inimmune Collaborates with Boston Children's Hospital to Develop Novel Adjuvants

Read More
More Investor News Found Here

About Inimmune

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics. The group has extensive expertise in synthetic and process chemistry, drug formulation, and immunology. Our pipeline includes innovative new treatments to harness the innate immune system in areas of critical patient need such as oncology, allergic rhinitis, food allergy, infectious disease vaccines, and novel antibiotics for bacterial infections.

Read More
Go

Pipeline

Inimmune’s focus is to discover and develop novel innate immune modulating compounds for treatment of a host of immune diseases. Our team is a world leader in the discovery and development of innate immune stimulants. Currently, the company’s pipeline is focused on utilizing several late-stage Toll-like receptor (TLR) agonists in immuno-oncology, food allergy, and allergic rhinitis. Next generation projects are focused on developing these agents as adjuvants for use with novel phage-based vaccines to prevent Gram-negative bacterial infections and for use with an opioid vaccine to prevent drug overdose.
Read More
Go
Infectious Disease
Allergy
Inimmune Pipeline
Click on any program to learn more.
Oncology
Vaccines
Autoimmunity
Adjuvants
Infectious Disease
Allergy
Inimmune Pipeline
Click on any program to learn more.
Oncology
Vaccines
Autoimmunity
Adjuvants

Pipeline

Inimmune’s focus is to discover and develop novel innate immune modulating compounds for treatment of a host of immune diseases. Our team is a world leader in the discovery and development of innate immune stimulants. Currently, the company’s pipeline is focused on utilizing several late-stage Toll-like receptor (TLR) agonists in immuno-oncology, food allergy, and allergic rhinitis. Next generation projects are focused on developing these agents as adjuvants for use with novel phage-based vaccines to prevent Gram-negative bacterial infections and for use with an opioid vaccine to prevent drug overdose.
Read More
Go

Inimmune Pipeline
Click on any program to learn more.

Autoimmunity
Allergy
Vaccines
Infectious
Disease
Oncology
Adjuvants

Partner with us

Inimmune is a fast-moving innovative biotechnology company focused on the discovery and development of novel immunotherapeutics for allergy, autoimmunity, and cancer. Inimmune has a deep pipeline of early and late pre-clinical assets and a strong intellectual property position poised to change the landscape of immunotherapy. The Inimmune team of industry professionals has an average of >15 years of biotech/pharmaceutical experience and a long track record of success in bringing new vaccine adjuvants and immunotherapeutics to the marketplace. The Inimmune management team is actively seeking partnerships and investors who share our vision to create and develop new safe and effective immunotherapeutics for the treatment of allergy, autoimmunity, and cancer.
Contact Us
Go

Careers Highlights

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics. The group has extensive expertise in synthetic and process chemistry, drug formulation, and immunology.

Our goal at Inimmune is to recruit, hire, and maintain a diverse workforce. Equal employment opportunity is good business. It is also the law. Equal opportunity applies to all aspects of employment, including recruitment, selection, hiring, training, transfer, promotion, termination, compensation, and benefits. 

Read More
Go

At Inimmune our team is advancing the next generation of immunotherapies and vaccine technology for the benefit of human kind.

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics.

Facebook-f Twitter Linkedin

Quick Links

Contact

  • 1121 E Broadway St, Ste 106, Missoula, MT, 59802
  • 406-541-5913
  • info@inimmune.com
© 2024 Inimmune Corp. All rights reserved.
Website Design by Digital Marketing Missoula
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go

TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING